Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease

Aim. To assess the dynamics of collagen metabolism markers during.

Material and methods. This open-label, controlled, age-randomized therapy in older patients with heart failure with mid-range ejection study included 162 patients with HFmrEF. Group 1 consisted of 82 fraction (HFmrEF) and coronary artery disease.  elderly patients (mean age, 68±5 years), group 2 — 80 elderly senile patients (mean age, 79±3 years). The levels of matrix metalloproteina-ses (MMP-1, MMP-9) and tissue inhibitor of metalloproteinases (TIMP-1) were determined by enzyme-linked immunosorbent assay using test systems MMP-1 ELISA, MMP-9 ELISA, and Human TIMP-1 ELISA, respectively.

Results. In elderly subjects taking bisoprolol, there was a decrease in collagen metabolism markers as follows: MMP-9 — by 43% (p<0,001), MMP-1 — ∆32%, TIMP-1 — ∆20% (p<0,01); nebivolol: MMP-9 — ∆50% (p<0,001), MMP-1 — ∆39%, TIMP-1 — ∆2% (p<0,01). Combined therapy with bisoprolol and eplerenone reduced the levels of MMP-9 by 52%, MMP-1 by 43% (p<0,001), and TIMP-1 by ∆32% (p<0,01), while combination of nebivolol and eplerenone decreased MMP-1 by 46%, MMP-9 by ∆59%, and TIMP-1 by ∆40% (p<0,001). In senile patients, bisoprolol decreased MMP-1 by 24%, MMP-9 by ∆39%, and TIMP-1 by ∆17% (p<0,01); nebivolol: MMP-9 — ∆46% (p<0,001), MMP-1 — ∆33%, TIMP-1 — ∆25% (p<0,01). Combined therapy with bisoprolol and eplerenone reduced the levels of MMP-1 by 40%, MMP-9 by ∆50% (p<0,001), and TIMP-1 by ∆26% (p<0,01), while combination of nebivolol and eplerenone decreased MMP-1 by 47%, MMP-9 by ∆57% (p<0,001), and TIMP-1 by ∆34% (p<0,01).

Conclusion. Twelve-month therapy with p-blockers (bisoprolol, nebivolol) in older patients with HFmrEF significantly reduced the levels of collagen metabolism markers MMP-1, MMP-9, and TIMP-1. The maximum effect was observed in the nebivolol+eplerenone group.

1. Lyu S, Yu L, Tan H, et al. Clinical characteristics and prognosis of heart failure with mid-range ejection fraction: insights from a multi-centre registry study in China. BMC Cardiovasc Disord. 2019;19(1):209. doi:10.1186/s12872-019-1177-1.

2. Gonzalez A, Schelbert EB, Dfez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives J Am Coll Cardiol. 2018;71:1696-706. doi: 10.1016/j.jacc.2018.02.021.

3. McDonald LT, Zile MR, Zhang Y, et al. Increased macrophage-derived SPARC precedes collagen deposition in myocardial fibrosis Am J Physiol Heart Circ Physiol. 2018;315:H92-H100. doi:10.1152/ajpheart.00719.2017

4. Ding Y, Wang Y, Jia Q, et al. Morphological and Functional Characteristics of Animal Models of Myocardial Fibrosis Induced by Pressure Overload. Int J Hypertens. 2020;2020:3014693. doi:10.1155/2020/3014693.

5. Gyongyosi M, Winkler J, Ramos I, et al. Myocardial fibrosis: biomedical research from bench to bedside. Eur J Heart Fail. 2017; 19(2):177-91. doi:10.1002/ejhf.696.

6. Neilan TG, Coelho-Filho OR, Shah RV, et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J Am Coll Cardiol Img. 2013;6:672-83. doi:10.1016/j.jcmg.2012.09.020.

7. Osipova OA, Golivets TP, Belousova ON, et al. Matrix metalloproteinases as collagen markers exchange with congestive cardiac insufficiency with an intermediate ejection fraction with patients with coronary heart disease and metabolic syndrome. JCR. 2020;7(10):567-70. doi:10.31838/jcr.0710.112.

8. Dushina AG, Lopina EA, Libis RA. Features of chronic heart failure depending on the left ventricular ejection fraction. Russian Journal of Cardiology. 2019;24(2):7-11. (In Russ.) doi:10.15829/1560-4071-2019-2-7-11.

9. Liang B, Zhao YX, Zhang XX, et al. Reappraisal on pharmacological and mechanical treatments of heart failure. Cardiovasc Diabetol. 2020;19(1):55. doi:10.1186/s12933-020-01024-5.

10. Tam TS, Wu MH, Masson SC, et al. Eplerenone for hypertension. Cochrane Database Syst Rev. 2017;2(2):CD008996. doi:10.1002/14651858.CD008996.pub2.

11. Ferreira JM, Ferreira SM, Ferreira MJ, Falcao-Pires I. Circulating Biomarkers of Collagen Metabolism and Prognosis of Heart Failure with Reduced or Mid-Range Ejection Fraction. Curr Pharm Des. 2017;23(22):3217-23. doi: 10.2174/1381612823666170317124125.

12. Raz-Pasteur A, Gamliel-Lazarovich A, Gantman A, et al. Mineralocorticoid receptor blockade inhibits accelerated atherosclerosis induced by a low sodium diet in apolipoprotein E-deficient mice. J Renin Angiotensin Aldosterone Syst. 2014;15(3):228-35. doi:10.1177/1470320312467558.